7Baggers
 The week in pharma: action, reaction and insight – week to September 26  The Pharma Letter Sun, 28 Sep 2025 10:56:33 GMT
 Published on: 2025-09-27 02:35:25  newser.com Sat, 27 Sep 2025 07:35:25 GMT
 fy2025 earnings estimate for genfit issued by hc wainwright  Defense World Sat, 27 Sep 2025 06:15:11 GMT
 fy2025 eps estimates for genfit lifted by leerink partnrs  Defense World Fri, 26 Sep 2025 18:00:43 GMT
 hc wainwright has pessimistic view of genfit fy2025 earnings  MarketBeat Fri, 26 Sep 2025 11:45:49 GMT
 fy2025 eps estimates for genfit lifted by leerink partnrs  MarketBeat Thu, 25 Sep 2025 12:20:53 GMT
 genfit (nasdaq:gnft) price target lowered to $7.00 at hc wainwright  Defense World Thu, 25 Sep 2025 06:51:15 GMT
 Genfit price target lowered to $7 from $9 at H.C. Wainwright  TipRanks Wed, 24 Sep 2025 10:41:21 GMT
 Genfit (GNFTF) Reports 41.7% Revenue Decline in First Half of 20  GuruFocus Wed, 24 Sep 2025 01:19:19 GMT
 genfit (gnftf) reports 41.7% revenue decline in first half of 20  GuruFocus Tue, 23 Sep 2025 06:05:56 GMT
 genfit’s 2025 mid-year financial and strategic update  TipRanks Tue, 23 Sep 2025 03:58:23 GMT
 genfit sa reports revenue decline and net loss  TipRanks Tue, 23 Sep 2025 03:53:59 GMT
 GENFIT S.A. Releases Half-Year Financial Report for 2025  TipRanks Mon, 22 Sep 2025 20:52:24 GMT
 genfit’s strategic shift and financial update for h1 2025  TipRanks Mon, 22 Sep 2025 20:32:24 GMT
 Genfit plans spending cut after ending VS-01 program in ACLF  The Pharma Letter Mon, 22 Sep 2025 13:17:30 GMT
 Genfit stock tumbles after discontinuing VS-01 liver failure treatment  Investing.com Mon, 22 Sep 2025 09:30:43 GMT
 Genfit prioritizes VS-01 development in urea cycle disorder  BioWorld MedTech Mon, 22 Sep 2025 07:00:00 GMT
 Genfit SA Reports Revenue Decline and Net Loss  TipRanks Mon, 22 Sep 2025 07:00:00 GMT
 Genfit’s 2025 Mid-Year Financial and Strategic Update  TipRanks Mon, 22 Sep 2025 07:00:00 GMT
 Earnings Scheduled For September 22, 2025  Benzinga Mon, 22 Sep 2025 07:00:00 GMT
 Genfit SA discontinues lead programme  European Biotechnology Magazine Sun, 21 Sep 2025 07:00:00 GMT
 GENFIT Discontinues VS-01 Program in ACLF to Focus on UCD  TipRanks Fri, 19 Sep 2025 07:00:00 GMT
 published on: 2025-09-18 03:37:29  خودرو بانک Thu, 18 Sep 2025 00:11:52 GMT
 published on: 2025-09-17 04:19:48  خودرو بانک Wed, 17 Sep 2025 00:52:16 GMT
 published on: 2025-09-16 06:15:56  newser.com Tue, 16 Sep 2025 11:15:56 GMT
 published on: 2025-09-14 00:16:28  newser.com Sun, 14 Sep 2025 05:16:28 GMT
 published on: 2025-09-13 16:46:11  newser.com Sat, 13 Sep 2025 21:46:11 GMT
 published on: 2025-09-11 02:51:45  Newser Thu, 11 Sep 2025 07:51:45 GMT
 published on: 2025-09-11 00:53:18  Newser Thu, 11 Sep 2025 05:53:18 GMT
 published on: 2025-09-08 08:17:52  Newser Mon, 08 Sep 2025 13:17:52 GMT
 published on: 2025-09-04 05:39:43  Newser Thu, 04 Sep 2025 10:39:43 GMT
 published on: 2025-09-03 09:19:06  Newser Wed, 03 Sep 2025 14:19:06 GMT
 published on: 2025-08-31 20:13:34  Newser Mon, 01 Sep 2025 01:13:34 GMT

Genfit SA
(NASDAQ:GNFT) 

GNFT stock logo

Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting primarily the liver and gastroenterology. The company's lead products include Elafibranor, which is in pivotal Phase III clinical trials for ...

Founded: 1999
Full Time Employees: 203
CEO: Pascal Prigent  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends